2 Trials to Test Oral BIIB122/DNL151 in Slowing Parkinson’s Progression

2 Trials to Test Oral BIIB122/DNL151 in Slowing Parkinson’s Progression

316109

2 Trials to Test Oral BIIB122/DNL151 in Slowing Parkinson’s Progression

Biogen and Denali Therapeutics are planning to launch two late-stage clinical trials to further evaluate the potential of their investigational oral therapy BIIB122/DNL151 in treating people with Parkinson’s disease. The Phase 3 and Phase 2b trials, expected to commence this year, will be led by Biogen and follow promising results from two previous Phase 1 clinical studies, according to a Denali corporate update. “We are looking forward to a high impact year in 2022, having accomplished several clinical and regulatory…

You must be logged in to read/download the full post.